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payer management. OBJECTIVES: To better understand the current and evolving
roles of CoE and national disease registries in the EU, including implications on the
price and management of orphan drugs, and to identify implications for further
evolution of rare disease specialty centers in theUS. Trends on the EUdevelopment
of CoE and national rare disease registries will be reviewed and expert opinion will
be consulted. RESULTS: Tools and data that will be available to both the payer
bodies and the CoE will be identified Examples of influence of CoE and disease
registries on the pricing and reimbursement of orphan drugs (e.g. CoE in France,
cancer registries in Italy) will be described. Implications of the use of this informa-
tion and data will be explored for EU payers. CONCLUSIONS: EU payer bodies will
gain increasing information and data necessary to further scrutinize the price and
reimbursement opportunity for orphan drugs, through the use of registries and
evaluation by CoE. Manufacturers should be prepared to understand and consider
partnerships with CoE in EU.
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Decision makers who undertake health technology assessments such as those
conducted by NICE, deliberatively consider a new technologies cost per QALY,
alongside other criteria (such as, equity, whether treatment is lifesaving and pa-
tient experience, etc) which are not captured in incremental cost-effectiveness
ratios alone. The intention to implement an explicit value based pricing scheme in
theUnitedKingdom in 2014 has sparked a debate regardingwhich elements should
be included in the assessment of value and how they should be combined and
traded-off against each other. Of importance is consideration to how values should
be derived to determine how different criteria should trade-off each other. This
debate is timely given that even where price is considered to be fixed during the
re-imbursement process (such as the current NICE process) such systems could be
seen implicitly determining value based price andmay influence pricing decisions.
Using an example presented in a recent review or multi-criteria decision making
(Thokala 2011) we compare four mechanisms by which different elements of
value could be explicitly and deterministically traded-off in order to provide an
overall estimate of a value based price.The mechanisms are:conventional cost
per QALY; MCDA; adjusted QALY approach; adjusted threshold approach; and a
net benefit approach. Hypothetical criteria incorporated into the decision mak-
ing process include equity, innovation, patient compliance and the quality of
evidence. Using these examples, we show that thesemethods are clearly related
in that they ultimately require estimates of monetary value to be placed on each
dimension of value, but may place different emphasis on the weightings given
to specific elements and the potential interactions between different elements.
The mechanism in which these monetary values are derived, must importantly
reflect societies values in trading off additional criteria for overall health gains.
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OBJECTIVES: Under the concept of pharmaceutical branch development (2011-
2020), social reimbursement system is going to be developed and implemented in
Ukraine. That will demand a use of central health technology assessment (HTA)
approach with appropriate instruments for its implementation. The aim of this
publication was to develop an instrument for HTA prioritization in Ukraine by
using qualitative approach. METHODS: A literature search was performed across
PudMed, Medline, and Cochrane. EUR-ASSESS report was analyzed. Factors impor-
tant for current health care decision making, data availability, and criteria impor-
tant for prioritization in the other countries were reviewed by the experts and
assessed on their applicability in Ukrainian health care setting. RESULTS: A list of
criteria that should be a basis for HTA prioritization in Ukraine was developed. The
criteria have different weight in accordance to their importance and data availabil-
ity. These criteria are the following: burden of disease, current size of state financ-
ing for this health care branch, potential benefit of intervention for individual
patient, disease prevalence, direct cost of intervention per patient, estimated bud-
get impact, current rate of the technology use, inclusion of a medical product into
standardized documents (clinical protocols, State formulary), additional aspects
with an impact on health policy. CONCLUSIONS: Factors important for HTA prior-
itization in the other countries can not be used without adaptation due to differ-
ences in health care systems, current decision-making processes, and data avail-
ability. Developed prioritization instrument should be used as a tool for future
health care insurance system in Ukraine.
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India’s health care requirements are different as different systems of medicine are
practiced. Only 15-20% of India’s population has access to modern medicines (all-
opathic medicines) whereas remaining population uses traditional systems such
as Ayurveda, Siddha, Unani, home remedies etc. People who have access to mod-
ern medicines have to spend out of pocket expenditure in order to have access to
health care facilities including hospital, diagnosis and medicines. Out of these
medicines are important for overall wellbeing population. Moreover only 10 % of
population is covered by health financing schemes including medical insurance.
Further a more than 1lakh (0.1 million) different brands of medicines flourish
Indian market with sometimes more than a 100 brands of same molecule. The
problem is manufacturers charge different prices for different brand names of
same molecule. Medical practitioners have various options to choose from to
prescribe these medicines and many a times it is observed that patients are
given costly medicines when they can be given an economical alternative. This
leads to financial burden on patients and health financing schemes including
private and public sector. This is due to a lack of standard pharmacoeconomics
guidelines in India. In presence of pharmacoeconomics guidelines it would be
simpler to identify an economical alternative that would be beneficial to patient
in particular and to society at large. In Asia countries like China, Taiwan, South
Korea, Thailand have taken steps in formulating pharmacoeconomics guide-
lines. Even other developing countries like South Africa, Brazil, Mexico have
taken steps to implement pharmacoeconomics guidelines. Country like India
should take proactive steps in order to design and implement pharmacoeco-
nomics guidelines.
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OBJECTIVES: To review the various options that the Centers for Medicare & Med-
icaid Services (CMS) has to review new drugs and biologics under its National
Coverage Determination (NCD) process, and conduct such review in the wake of its
recent NCD for sipuleucel-T. This analysis seeks to better understand if CMS will
employ NCD’s to centralize its control over drug coverage.METHODS: NCD’s have
primarily been applied to drugs and devices that have had some associated issue
that could result in productmisuse. Suchmisusemay lead to unwarranted use, use
that increases costs without commensurate outcomes, us that may impact patient
safety or use outside of indication that is not deemed reasonable and necessary.
Review of the most recent CMS NCD covering sipuleucel-T provides some indica-
tion as to how CMS may use its NCD authority to control product coverage.
RESULTS:Analysis of past CMSNCD’s indicates that CMShas historically regulated
devices under NCD at a greater rate than drugs or biologics when there has been a
concern over unwarranted use that would increase product utilization and costs
over existing products. This has resulted in coverage and payment being either
restricted or tied to other products. In the case of sipuleucel-T, CMS subjected it to
review under NCD due to the fact that it is a vaccine, its cost is high and the high
potential for use outside of castration resistant prostate cancer as reported in the
media. The result of CMS’ review was an NCD that allowed for coverage of on label
use of sipuleucel-T, but reserved off label coverage decisions to individual
contractors. CONCLUSIONS: Using CMS’ sipuleucel-T NCD as a potential predictor
of future NCD actions, CMS may continue to make overall coverage decisions re-
garding labeled indications, but defer off label coverage determinations to local
contractors.
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OBJECTIVES: A survey was conducted to establish the extent to which environ-
mental factors impact payers and payer influencers, aswell asmacro-environmen-
tal policy and purchasing decisions. METHODS: Qualitative telephone interviews
were undertaken with subjects in the UK, Germany, France, Spain and Sweden.
RESULTS: Though still in their infancy, environmental consequences were con-
firmed as becoming an important dimension of health technology assessment
(HTA). Regulation and best practice guidelines designed to limit the environmental
impact of purchasing strategy were identified at local, regional, or national level in
Sweden and the UK. Poor data availability was identified as a major challenge,
undermining the credibility of claims related to environmental factors. To avoid a
“green-wash” of health technologies presented to decision makers along the value
chain, environmental evaluations will need to provide robust, standardized infor-
mation concerning a wide range of criteria, such as waste management, energy
containment or Carbon footprints. Health technology development, aswell asmar-
ket accessmanagement will have to anticipate an evolving awareness for environ-
mental matters, in both emerging and mature markets. Their ultimate translation
into policy and regulation is anticipated to be a combination of regulatory control
and progressive application of Pigovian costs.CONCLUSIONS: Regulatory control is
likely to be rolled out through updated operating procedures in existing structures,
such as public agencies in charge of homologation, HTA or reimbursement. This is
not likely to happen in a consistent manner across the various national healthcare
systems. Payers are expected to deal not only with evolving enhanced recommen-
dations and standards, but might choose to pro-actively reflect environment-re-
lated viewpoints themselves, when defining future specifications. In such a sce-
nario, strategic purchasers will encounter a framework of versatile requirements
and incentives, and are likely to opt for health technologies that are able to present
a solid environmental case.
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